Market News AIOpen the app

PTGX stock news · Protagonist Therapeutics

Stories about Protagonist Therapeutics (PTGX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PTGX

Follow Protagonist Therapeutics (PTGX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PTGX
Free on the App Store and Google Play, or on the web.
  1. Nov 10, 2026, 2:33 PM ET · Opinion

    Wedbush says to keep buying Protagonist Therapeutics and set the price target at $173.

    Neutral

    Protagonist Therapeutics received a reaffirmed Buy rating from Wedbush, which kept its $173 price target. This repeats an analyst's view, not new company results, so it does not change the company's outlook.

  2. Sep 1, 2026, 9:10 AM ET · Market

    Analysts project Apple reaching $303: A look at 10 leading forecasts for Tuesday.

    Good for PTGX

    BMO Capital lifted Protagonist Therapeutics' target and kept an Outperform rating, which is supportive for the stock.